Endocyte (ECYT) Inactive 10-Q2017 Q2 Quarterly report

Filed: 9 Aug 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accomplish, adaptor, adequate, adequately, affording, aggregate, attack, attract, begun, biotechnology, bring, candidate, cGMP, close, closing, competing, competition, costly, decline, desirable, desire, difficult, disagree, Disposal, disruption, distract, dropout, economic, efficiency, evidenced, Exit, expenditure, extensive, external, fail, failure, FDA, fewer, Food, force, foregoing, Good, governmental, guarantee, heightened, high, highest, hire, hiring, human, impairment, impede, implement, inability, industry, institutional, interpretation, intrinsic, introduce, IRB, key, label, labeling, lack, monitor, morale, motivate, multiplying, oversight, partner, personnel, pivotal, platform, policy, Practice, prevent, prevented, private, produced, prospective, protocol, qualified, reach, recruitment, refocused, relied, reorganization, reputation, request, retention, safe, scientific, slower, sooner, state, stopped, stopping, strategy, stream, succeed, suffered, suitable, support, surveillance, suspended, talent, test, testing, unforeseen, unknown, workforce

Removed: cell, dosing, endometrial, inflammatory, lung, NSCLC, treated, vintafolide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ECYT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael A. Sherman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Endocyte, Inc. on Form 10-Q for the quarter ended June 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Endocyte, Inc. for the periods covered by such Quarterly Report on Form 10-Q.

August 9, 2017
	/s/ Michael A. Sherman
	Name:	Michael A. Sherman
	Title:	President and Chief Executive Officer

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael T. Andriole, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Endocyte, Inc. on Form 10-Q for the quarter ended June 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Endocyte, Inc. for the periods covered by such Quarterly Report on Form 10-Q.


August 9, 2017
	/s/ Michael T. Andriole
	Name:	Michael T. Andriole
	Title:	Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.